{"organizations": [], "uuid": "5035547cda8843e50b67b94c741f9c3af7d6fe71", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-valneva-and-emergent-biosolutions/brief-valneva-and-emergent-biosolutions-start-phase-1-clinical-study-to-evaluate-vaccine-candidate-against-zika-virus-idUSASM000JQZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T23:24:00.000+02:00", "replies_count": 0, "uuid": "5035547cda8843e50b67b94c741f9c3af7d6fe71"}, "author": "", "url": "https://www.reuters.com/article/brief-valneva-and-emergent-biosolutions/brief-valneva-and-emergent-biosolutions-start-phase-1-clinical-study-to-evaluate-vaccine-candidate-against-zika-virus-idUSASM000JQZ", "ord_in_thread": 0, "title": "BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "evaluate vaccine candidate against zika virus", "sentiment": "negative"}, {"name": "valneva", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "vaccine candidate against zika virus reuters staff", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 24 PM / Updated 10 minutes ago BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus Reuters Staff 1 Min Read Feb 26 (Reuters) - VALNEVA SE: * EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS * ‍INITIAL DATA FROM TRIAL ARE EXPECTED TO BE AVAILABLE IN LATE 2018 OR EARLY 2019​ * AFTER PHASE 1 DATA, EMERGENT HAS OPTION TO DEVELOP VACCINE UNDER LICENSE AGREEMENT WITH VALNEVA AT EUR 5 MILLION​ * LICENSE ‍AGREEMENT PROVIDES VALNEVA POTENTIAL ADDITIONAL MILESTONE PAYMENTS OF UP TO EUR 44 MILLION​ * LICENSE ‍AGREEMENT TO GIVE CO RIGHT TO NEGOTIATE WITH EMERGENT EXCLUSIVE COMMERCIALIZATION RIGHTS IN EUROPE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-02-26T23:24:00.000+02:00", "crawled": "2018-02-26T23:44:05.009+02:00", "highlightTitle": ""}